Athira Pharma Inc (ATHA) - Total Liabilities
Based on the latest financial reports, Athira Pharma Inc (ATHA) has total liabilities worth $64.36 Million USD as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore ATHA shareholders equity momentum to track the company's year-over-year net asset growth rate.
Athira Pharma Inc - Total Liabilities Trend (2018–2025)
This chart illustrates how Athira Pharma Inc's total liabilities have evolved over time, based on quarterly financial data.
Athira Pharma Inc Competitors by Total Liabilities
The table below lists competitors of Athira Pharma Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Embrace Change Acquisition Corp Ordinary Shares
NASDAQ:EMCG
|
USA | $33.67 Million |
|
Plus Therapeutics Inc
NASDAQ:PSTV
|
USA | $7.96 Million |
|
VisDynamics Holdings Bhd
KLSE:0120
|
Malaysia | RM6.09 Million |
|
Sangsin Brake
KO:041650
|
Korea | ₩345.20 Billion |
|
Korea Circuit Co Ltd
KO:007815
|
Korea | ₩601.95 Billion |
|
Davolink Inc.
KQ:340360
|
Korea | ₩25.53 Billion |
|
Worth Peripherals Limited
NSE:WORTH
|
India | Rs387.40 Million |
|
Podium Minerals Ltd
AU:POD
|
Australia | AU$1.43 Million |
Liability Composition Analysis (2018–2025)
This chart breaks down Athira Pharma Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see ATHA market cap overview.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.88 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 2.32 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.70 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Athira Pharma Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Athira Pharma Inc (2018–2025)
The table below shows the annual total liabilities of Athira Pharma Inc from 2018 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $64.36 Million | +361.77% |
| 2024-12-31 | $13.94 Million | -53.63% |
| 2023-12-31 | $30.06 Million | +30.59% |
| 2022-12-31 | $23.02 Million | +110.69% |
| 2021-12-31 | $10.92 Million | +106.85% |
| 2020-12-31 | $5.28 Million | -75.90% |
| 2019-12-31 | $21.91 Million | +10.55% |
| 2018-12-31 | $19.82 Million | -- |
About Athira Pharma Inc
Athira Pharma, Inc., clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. Its product pipeline includes ATH-1105 for the treatment of amyotrophic lateral sclerosis, which is in phase 1 clinical trial; ATH-1020 for the treatment of neurodegenerative diseases, which is phase 1 clinical trial, as well as early compounds… Read more